Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study
Authors:
- Khalid El BairiKhalid El Bairi
- Salma NajemSNSalma Najem
- Arman Reza ChowdhuryACArman Reza Chowdhury
- Abeid OmarAOAbeid Omar
- Omar AbdihamidOAOmar Abdihamid
- Laure-Anne TeuwenLTLaure-Anne Teuwen
- Nada BenhimaNBNada Benhima
- Ainhoa MadariagaAMAinhoa Madariaga
- Fernando Cristobal DiazFDFernando Cristobal Diaz
- Kristina JeneiKJKristina Jenei
- 1 July 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400167
Abstract
PURPOSE: Conflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulations on reporting COI in high-income countries (HICs), little is known about their reporting in low- and middle-income countries (LMICs). Oncology Transparency Under Scrutiny and Tracking (ONCOTRUST-1) is a pilot global survey to explore the knowledge and perceptions of oncologists regarding COI. MATERIALS AND METHODS: We designed an online 27-question–based survey in the English language to explore the perceptions and knowledge of oncologists regarding COI, with an emphasis on LMICs. Descriptive statistics and the Consensus-Based Checklist for Reporting of Survey Studies guidelines were used to report the findings. RESULTS: ONCOTRUST-1 surveyed 200 oncologists, 70.9% of them practicing in LMICs. Median age of the respondents was 36 (range, 26-84) years; 47.5% of them were women. Of the respondents, 40.5% reported weekly visits by pharmaceutical representatives to their institutions. Regarding oncologists' perceptions of COI that require disclosure, direct financial benefits, such as honoraria, ranked highest (58.5%), followed by gifts from pharmaceutical representatives (50%) and travel grants for attending conferences (44.5%). By contrast, personal or institutional research funding, sample drugs, consulting or advisory board, expert testimony, and food and beverage funded by pharmaceutical industry were less frequently considered as COI. Moreover, only 24% of surveyed oncologists could correctly categorize all situations representing a COI. CONCLUSION: These findings underscore the importance of clear guidelines, education, and transparency in reporting COI in oncology. This hypothesis-generating pilot survey provided the rationale for ONCOTRUST-2 study, which will compare perceptions of COI among oncologists in LMICs and HICs.Keywords
This publication has 28 references indexed in Scilit:
- Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials Led by High-Income CountriesJAMA Network Open, 2022
- Examination of Potential Industry Conflicts of Interest and Disclosures by Contributors to Online Medical Resource DatabasesJAMA Network Open, 2022
- Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice GuidelinesThe Oncologist, 2021
- A Consensus-Based Checklist for Reporting of Survey Studies (CROSS)Journal of General Internal Medicine, 2021
- Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019Cancer, 2020
- Quantification of Conflicts of Interest in an Online Point-of-Care Clinical Support WebsiteScience and Engineering Ethics, 2019
- Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelinesCancer, 2019
- Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in JapanJAMA Network Open, 2019
- Decoding disclosure: Comparing conflict of interest policy among the United States, France, and AustraliaHealth Policy, 2018
- Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline AuthorsJAMA Oncology, 2016